Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Graphite Bio, Inc. - Common Stock (NQ:GRPH)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Graphite Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's trading, 71 companies set new 52-week lows. 
Via Benzinga
Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study
 
Via Benzinga
BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock
 
Via Benzinga
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday
 
Via Benzinga
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
From Graphite Bio, Inc.
Via Business Wire
5 Value Stocks To Watch In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
Upgrades 
Via Benzinga
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
From Graphite Bio, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Shares Soar As Initial-Stage Blood Cell Disorder Study Launched
Graphite Bio (NASDAQ: GRPH) announced the initiation of patient dosing in the Phase 1/2 CEDAR trial with its asset GPH101 (nulabeglogene autogedtemcel) in people with sickle cell disease (SCD). 
Via Benzinga
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Jefferies Healthcare Conference
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio, Inc. (NASDAQ:GRPH) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/26/2022 -- An investigation on behalf of current long-term investors in shares of Graphite Bio, Inc. (NASDAQ:GRPH) was announced over potential breaches of fiduciary... 
Via SBWire
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
From Graphite Bio, Inc.
Via Business Wire
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.